Camurus Q3 operating result jumps 40% to SEK 322 million; Q3 total revenues rise 28% to SEK 724 million

• Camurus’ third-quarter 2026 operating result rose 40% to SEK 322 million; total revenues increased 28% to SEK 724 million.
• Brixadi royalty revenue climbed 23% to SEK 137 million.
• The FDA accepted the CAM2029 acromegaly application resubmission for review, setting a December 18, 2026, target action date.
• Unchanged 2026 guidance puts revenues and operating result in the upper halves of SEK 2.6–2.9 billion and SEK 0.9–1.2 billion, respectively.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Camurus AB published the original content used to generate this news brief via Cision (Ref. ID: 202611050100BITN____UKPR__EN_20261104-BIT-4777-0) on November 05, 2026, and is solely responsible for the information contained therein.